Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Nasopharyngeal Carcinoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Plasmacytoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

silmitasertib 1daratumumab 1Leukapheresis 1Drug Combinations 1CF regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Plasmacytoma × CF regimen × Clear all
NCT04665076 2020-12-11

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
60 enrolled
Plasma cell

Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡